HDAC9 and neoplasm: Scriptaid also impairs CAF’s tumour-supportive properties in vitro and in vivo; thus, Scriptaid or similar HDAC inhibitors may represent a class of molecular therapeutics that target both cancer cells and stromal cells in the microenvironment of solid tumours.